NSRGY - Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

• Seres Therapeutics reports new data concerning safety and effectiveness of SER-109 for treating recurrent C.difficile infection.
• This completes Seres package for BLA (Biologics License Application) to the FDA.
• If successful SER-109 would be the first microbic drug to receive BLA approval from the FDA.
• If FDA approval of SER-109 were received, it would surely lead to revaluation of the fortunes of the company and its share price. This is a near term opportunity.

For further details see: